NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis $43.63 -0.55 (-1.24%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$43.60 -0.03 (-0.06%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Alkermes Stock (NASDAQ:ALKS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alkermes alerts:Sign Up Key Stats Today's Range$43.15▼$44.1550-Day Range$39.08▼$50.1852-Week Range$27.00▼$55.67Volume884,579 shsAverage Volume2.27 million shsMarket Capitalization$7.32 billionP/E Ratio114.82Dividend YieldN/APrice Target$54.47Consensus RatingModerate Buy Company Overview Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders. The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults. Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts. The company serves patients primarily through the United States pharmaceutical market and uses proprietary drug-delivery technologies, including long-acting injectable formulations, as part of its approach to developing treatments for complex and chronic conditions.AI Generated. May Contain Errors. Read More Alkermes Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreALKS MarketRank™: 3.209255533195 of 5 starsAlkermes scored higher than 64% of companies evaluated by MarketBeat, and ranked 281st out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 1 strong buy rating, 12 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialAlkermes has a consensus price target of $54.47, representing about 24.8% upside from its current price of $43.63.Amount of Analyst CoverageAlkermes has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alkermes' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alkermes are expected to grow in the coming year, from ($0.57) to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 114.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 114.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.33.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alkermes' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.13% of the float of Alkermes has been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 6.28.Change versus previous monthShort interest in Alkermes has recently increased by 17.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.22 News SentimentAlkermes has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Alkermes this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,752,181.00 in company stock.Percentage Held by Insiders4.59% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alkermes' insider trading history. Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALKS Stock News HeadlinesAlkermes (ALKS) Expected to Post Earnings on WednesdayOctober 21, 2026 | americanbankingnews.comAlkermes (ALKS) Receives a Buy from NeedhamOctober 20, 2026 | theglobeandmail.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.October 25 at 1:00 AM | Digest Publishing (Ad)Alkermes to Report Third Quarter Financial Results on November 3, 2026October 20, 2026 | finance.yahoo.comTruist Financial Begins Coverage on Alkermes (NASDAQ:ALKS)October 18, 2026 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Stock Has Consensus Price Target of $54.47October 17, 2026 | americanbankingnews.comAlkermes reinstated Buy at Truist on narcolepsy opportunityOctober 16, 2026 | seekingalpha.comInsider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 2,034 Shares of Company StockOctober 3, 2026 | insidertrades.comSee More Headlines ALKS Stock Analysis - Frequently Asked Questions How have ALKS shares performed this year? Alkermes' stock was trading at $27.98 at the beginning of the year. Since then, ALKS stock has increased by 55.9% and is now trading at $43.63. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) announced its earnings results on Thursday, February, 26th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.43 by $0.14. The firm's revenue was down 10.6% on a year-over-year basis. Read the conference call transcript. Does Alkermes have any subsidiaries? Alkermes subsidiaries include Rodin Therapeutics. Who are Alkermes' major shareholders? Alkermes' top institutional shareholders include Robeco Institutional Asset Management B.V. (0.03%), Yousif Capital Management LLC (0.03%), Nicollet Investment Management Inc. (0.03%) and State of Alaska Department of Revenue (0.02%). Insiders that own company stock include David Joseph Gaffin, Shane Cooke, Christian Todd Nichols, Craig C Hopkinson, Christopher I Wright, Cato T Laurencin and Nancy Lynn Md Snyderman. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), Intel (INTC), Gilead Sciences (GILD) and Alibaba Group (BABA). Company Calendar Last Earnings2/26/2026Today10/25/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 11 days, ALKS's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,050Year Founded1987Price Target and Rating Average Price Target for Alkermes$54.47 High Price Target$65.00 Low Price Target$36.00 Potential Upside/Downside+24.8%Consensus RatingModerate Buy Rating Score (0-4)2.68 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)$0.38 Trailing P/E Ratio114.82 Forward P/E RatioN/A P/E GrowthN/ANet Income$241.66 million Net Margins3.96% Pretax Margin5.84% Return on Equity4.15% Return on Assets2.19% Debt Debt-to-Equity Ratio0.82 Current Ratio2.30 Quick Ratio1.85 Sales & Book Value Annual Sales$1.67 billion Price / Sales4.39 Cash Flow$1.67 per share Price / Cash Flow26.06 Book Value$11.02 per share Price / Book3.96Miscellaneous Outstanding Shares167,763,000Free Float160,063,000Market Cap$7.32 billion OptionableOptionable Beta0.32 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ALKS) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.